Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
... resulted
in a marked and sustained decrease in
seizure frequency over the long-term(1).
Results ... add-on treatment experienced a
mean reduction in
seizure frequency of more than 61% (95%CI: ... had achieved at least a 50% reduction in
seizure frequency with
Zebinix(R) treatment(1).
...
Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults
... in helping patients move closer to the goal of
seizure freedom," said Steven S. Chung, MD, Director of ... those recently diagnosed who have not achieved
seizure control on current therapy, to those who have ... with epilepsy, less than half (47%) attained
seizure control with the first AED
More than 30% ...
Phase III Data Demonstrate Efficacy and Tolerability of Carisbamate as an Adjunctive Therapy for Partial Onset Seizures
... treatment success
is not only determined by
seizure control, but equally by tolerability, which
is ... demonstrate benefit
of carisbamate in reducing
seizure frequency in some patients with partial
onset ... endpoints were median percent reduction in
seizure frequency in the
double blind phase compared to ...
New Data Show Efficacy of Zebinix(TM) in the Treatment of Epilepsy
... and demonstrated
sustained reduction in partial
seizure frequency during a one-year open
label ... a patient's
day-to-day life, as well as effective
seizure control," said Professor E.
Ben-Menachem, ... Sweden. "In addition to sustained
reductions in
seizure frequency, Zebinix(TM) also demonstrated ...
Data Show Rufinamide, an Investigational Adjunctive Treatment for Lennox- Gastaut Syndrome, Reduced Drop Attacks by More Than 40%
... Ohio. "Existing
antiepileptics offer limited
seizure control and there may be difficulties
with ... AEDs.
The median percentage reduction in total
seizure frequency from
baseline was greater in the ... 42.5%
median percentage reduction in tonic-atonic
seizure (drop attack) frequency
per 28 days from baseline ...
Status of the E2007 (perampanel) Development Program
... pentylenetetrazole,
audiogenic and kindling
seizure models) suggested that perampanel may ... seizures. There was a 40% median
seizure reduction in the
perampanel arm and a 2% median
seizure increase in the placebo arm. The
responder rate, ...
Keppra XR(TM) Extended-Release Tablets Filed with the FDA
... The study met its primary endpoint for
seizure reduction over placebo
during the treatment ... to the extended-release
levetiracetam group had
seizure frequency per week reduced by 75-100%,
compared ... seizures and 8.9% were free from any type of
seizure over
the treatment period, compared to 2.5% and ....
UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets
... Keppra XR(TM) significantly reduced partial onset
seizure frequency when
administered as adjunctive ... tablets significantly
reduced partial onset
seizure frequency when administered as adjunctive
therapy ... The study met its primary endpoint for
seizure reduction over placebo
during the treatment ...
New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
... XR achieved at least a 50 percent
reduction in
seizure frequency compared to 24 percent of patients ... XR
taken once- daily significantly reduced
seizure frequency among previously
uncontrolled patients. ... median percent reduction from baseline
in partial
seizure frequency. Study results showed that Lamictal ...
New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal
...
NUCYNTA(TM) has not been systematically evaluated in patients with a
seizure disorder, and such patients were excluded from clinical studies. NUCYNTA(TM) should be prescribed with care in patients with a history of a
seizure disorder or any condition that would put the patient at risk of seizures. ...
RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder
...
RISPERDAL(R) CONSTA(R) should be used cautiously in people with a
seizure disorder, who have had seizures in the past, or who have conditions that ... with a history of seizures or with conditions that potentially lower
seizure threshold.
Dysphagia: Esophageal dysmotility and aspiration can ...
VIDEO from Medialink and the Epilepsy Foundation: New Study Suggests Different Versions of the Same Epilepsy Medication Can Be Harmful
... included. These variations can mean the difference between being
seizure free and suddenly having a
seizure while driving on the freeway," said Dr. Brien Smith, Senior Staff ...
New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures
... should be gradually withdrawn to minimize the potential of increased
seizure frequency.
Dosing must be individualized according to the ... and defined by two or more unprovoked seizures. There are many different
seizure types and epileptic syndromes. Forty percent of patients taking only one ...
Data Presented at AAN Support Potential for Adjunctive use of Intravenous Lacosamide as Short-Term Replacement for Oral Treatment in Partial Epilepsy
... oral antiepileptic drug. In these circumstances, and in order to
maintain
seizure control, a short-term, alternative administration of their
antiepileptic ... significantly greater 50% responder rates
and reductions in median
seizure frequency were seen versus placebo. The
most common adverse events of ...
Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
... a car, operating machines, or doing things that require you to be alert.
INVEGA((R)) SUSTENNA(TM) should be used cautiously in people with a
seizure disorder, who have had seizures in the past, or who have conditions that increase their risk for seizures.
Call your doctor right away if you ...
Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)
... new onset or exacerbation of clinical symptoms and/or radiographic evidence of demyelinating disease. Rare cases of neurological disorders, including
seizure disorder, optic neuritis, and peripheral neuropathy have been reported in patients treated with CIMZIA; the causal relationship to CIMZIA remains ...
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)
... before talking to your healthcare professional. Avoid alcohol while on paliperidone.
Paliperidone should be used cautiously in people with a
seizure disorder, who have had seizures in the past, or who have conditions that increase their risk for seizures.
Extrapyramidal Symptoms (EPS) are ...
Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy
... by recurrent, unprovoked seizures, is a change in
sensation, awareness or behavior caused by an electrical disturbance in the
brain. The kind of
seizure a person has depends on which part and how much of
the brain is affected by the disturbance. Primary generalized seizures involve
the entire brain ...
Observational Study Finds Changes in Medicare Reimbursement for Erythropoiesis-Stimulating Agents Associated With Increased Need for Blood Transfusion
... to other erythropoietic proteins.
The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a
seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes, or hypercoagulable disorders).
In some ...
FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
... potentially hazardous tasks such as driving a car or operating machinery. Tapentadol should be prescribed with care in patients with a history of a
seizure disorder or any condition that would put the patient at risk of seizures.
The development of a potentially life-threatening serotonin ...
Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting
... erythropoietic proteins. -- The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a
seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes, or hypercoagulable disorders). -- In ...
New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria
... management, as clinically indicated.
Carbapenems may reduce serum valproic acid concentrations to
subtherapeutic levels, resulting in loss of
seizure control. Serum valproic
acid concentrations should be monitored frequently after initiating
carbapenem therapy. Alternative antibacterial or ...
CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
... new onset or exacerbation of clinical symptoms and/or radiographic
evidence of demyelinating disease. Rare cases of neurological disorders,
including
seizure disorder, optic neuritis, and peripheral neuropathy have
been reported in patients treated with CIMZIA; the causal relationship to
CIMZIA remains ...
CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients
... new onset or exacerbation of clinical symptoms and/or radiographic
evidence of demyelinating disease. Rare cases of neurological disorders,
including
seizure disorder, optic neuritis, and peripheral neuropathy have
been reported in patients treated with CIMZIA; the causal relationship to
CIMZIA remains ...
CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients
... new onset or exacerbation of clinical symptoms and/or radiographic
evidence of demyelinating disease. Rare cases of neurological disorders,
including
seizure disorder, optic neuritis, and peripheral neuropathy have
been reported in patients treated with CIMZIA; the causal relationship to
CIMZIA remains ...
FDA Requires Additional Information on DORIBAX for Treatment of Hospital-Acquired Pneumonia
... management, as clinically indicated.
Carbapenems may reduce serum valproic acid concentrations to
subtherapeutic levels, resulting in loss of
seizure control. Serum valproic
acid concentrations should be monitored frequently after initiating
carbapenem therapy. Alternative antibacterial or ...
New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder
... Due to the voluntary nature of these reports
it is not possible to reliably estimate frequency or establish a causal
relationship. Increased
seizure activity or decreased phenytoin levels have
been reported in patients receiving phenytoin concomitantly with Welchol.
Reduced International ...
Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated
... Due to the voluntary nature of these reports
it is not possible to reliably estimate frequency or establish a causal
relationship. Increased
seizure activity or decreased phenytoin levels have
been reported in patients receiving phenytoin concomitantly with Welchol.
Reduced International ...
Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions
... to other erythropoietic proteins. -- The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a
seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes or hypercoagulable disorders). -- In some ...
Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
... allergic reactions have been seen in some patients
during ELAPRASE infusions. Reactions included difficulty breathing, lack of
oxygen,
seizure or loss of consciousness, hives, and/or swelling of the
throat or tongue. Patients received an antihistamine to reverse the
allergic reaction or ...
Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease
... new onset or exacerbation of clinical symptoms and/or radiographic
evidence of demyelinating disease. Rare cases of neurological disorders,
including
seizure disorder, optic neuritis, and peripheral neuropathy have
been reported in patients treated with Cimzia(R); the causal relationship
to Cimzia(R) ...
New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
... to other erythropoietic proteins. -- The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a
seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes or hypercoagulable disorders). -- In some ...
Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings
... to other erythropoietic proteins. -- The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a
seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes or hypercoagulable disorders). -- In some ...
Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
... to other erythropoietic proteins. -- The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a
seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes or hypercoagulable disorders). -- In some ...
Totality of Available Data Reaffirms PROCRIT(R) (Epoetin alfa) Is Safe and Effective When Used Appropriately as Labeled to Treat Chemotherapy-Induced Anemia
... to other erythropoietic proteins. -- The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a
seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes or hypercoagulable disorders). -- In some ...
Observational Data Show Transfusion Patterns in Chemotherapy-Induced Anemia Patients Receiving Erythropoiesis-Stimulating Agents
... to other erythropoietic proteins. -- The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a
seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes or hypercoagulable disorders). -- In some ...
Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
... Due to the voluntary nature of these reports
it is not possible to reliably estimate frequency or establish a causal
relationship. Increased
seizure activity or decreased phenytoin levels have
been reported in patients receiving phenytoin concomitantly with Welchol.
Reduced International ...
Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
... seizures (ARS) are bouts of acute
seizure activity occurring within a 24-hour period in adults and a 12-hour
period in children. ARS, also called
seizure clusters, occurs in a small
subset of patients with epilepsy who regularly experience breakthrough
seizures in flurries or clusters despite treatment ...
PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting
... to other erythropoietic proteins. -- The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a
seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes or hypercoagulable disorders). -- In some ...
This Thanksgiving Give the Gift of Good Health - Remind Family and Friends to Get a Flu Shot.
... cancer treatments) -- Adults and children who have certain muscle or nerve disorders (e.g. cognitive dysfunction, spinal cord injuries,
seizure disorders, or other neuromuscular disorders) that can compromise respiratory function or the handling of respiratory secretions or that can ...